Clinical Research Studies of Atimociclib in HR+/HER2- and/or HER2+ Breast Cancer
Clinical Research Studies of Atimociclib in HR+/HER2- and/or HER2+ Breast Cancer supports investigators studying atimociclib combinations to generate clinical evidence for breast cancer treatment.
Browse similar grants
Funder: Pfizer Inc.
Due Dates: January 12, 2027 (Concept) | May 7, 2027 (Invited full proposals)
Funding Amounts: $8,000,000 total budget for up to 6 clinical studies; 3-year projects
Summary: Supports investigator-sponsored clinical research generating evidence for atimociclib combinations in HR+/HER2- metastatic and/or HER2+ breast cancer.
Key Information: Both the institution and PI must be based in an eligible country; only accepted concepts advance to full proposals.
Description
Pfizer’s competitive research grant program supports interventional Investigator Sponsored Research generating clinical evidence for atimociclib combination approaches in HR+/HER2- metastatic breast cancer and/or HER2+ breast cancer. Priorities include post-adjuvant CDK4/6 inhibitor recurrence biology, HR+/HER2- metastatic combination strategies, and HER2+ signal-seeking studies.
The program seeks clinical translational research illustrating genomic profiles and treatment strategies after adjuvant CDK4/6 inhibitor progression, studies exploring atimociclib’s clinical utility in selected HER2+ patients, and combinations with existing or emerging standards of care in HR+ metastatic disease. Early breast cancer studies may be considered when sufficient supporting data justify research in a potentially curative setting. Pfizer makes funding decisions through internal review; investigators remain responsible for the independent study’s design, implementation, sponsorship, and conduct.
